[Extract from initial text]: The extreme and peculiar susceptibility of paroxysmal noc- turnal haemoglobinuria (PNH) red cells to activated comple- ment is the main mechanism of intravascular haemolysis and anaemia in this acquired disease. Thus, the introduction of complement 5 (C5) inhibition by a monoclonal antibody, ecu- lizumab, has been a major advance in the clinical management of PNH
The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab
Maria De Angioletti;
2023
Abstract
[Extract from initial text]: The extreme and peculiar susceptibility of paroxysmal noc- turnal haemoglobinuria (PNH) red cells to activated comple- ment is the main mechanism of intravascular haemolysis and anaemia in this acquired disease. Thus, the introduction of complement 5 (C5) inhibition by a monoclonal antibody, ecu- lizumab, has been a major advance in the clinical management of PNHFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
prod_476800-doc_195000.pdf
Open Access dal 19/01/2024
Descrizione: "This is the peer reviewed version of the following article: Sica, M., Barone, F., Nannelli, C., Ricci, P., Marano, L., De Angioletti, M., Di Bona, E., Risitano, A.M. and Notaro, R. (2023), The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab. Br J Haematol, 201: e1-e4, which has been published in final form at https://doi.org/10.1111/bjh.18662. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited."
Tipologia:
Versione Editoriale (PDF)
Licenza:
Altro tipo di licenza
Dimensione
1.37 MB
Formato
Adobe PDF
|
1.37 MB | Adobe PDF | Visualizza/Apri |
|
prod_476800-doc_196990.pdf
solo utenti autorizzati
Descrizione: The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells ...
Tipologia:
Versione Editoriale (PDF)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.37 MB
Formato
Adobe PDF
|
1.37 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
